Financials

News Discussions Technicals Forecast Seasonals

NP5 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to NEWRON PHARMACEUT. EO-,20 operating, investing, and financing activities

NP5 free cash flow for H2 24 is -8.66 M EUR. For 2024, NP5 free cash flow was -17.86 M EUR and operating cash flow was -17.85 M EUR.

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: EUR

TTM

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—